Sanofi and POZEN Sign Commercial Agreement for PA8140/PA32540 Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sanofi and POZEN Sign Commercial Agreement for PA8140/PA32540 Tablets



Sanofi and the biopharmaceutical company POZEN, have signed a license agreement for the commercialization of POZEN's tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet (i.e, PA), PA8140 and PA32540. Under the agreement, Sanofi will have rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. POZEN will receive an upfront payment of $15 million and be eligible for precommercial milestone payments of up to $20 million and other future milestone payments and royalties on product sales.

Sanofi US will have responsibility for all sales, marketing, ongoing manufacturing, and future development for the licensed PA products in the US. POZEN will retain responsibility for obtaining approval of the new drug application (NDA), after which time POZEN will transfer the NDA to Sanofi US. The NDA was submitted in March 2013 and accepted for filing in May 2013 by FDA.

Source: Sanofi

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here